Cleo Receives Strategic Growth Investment to Accelerate $5.5 Billion Ecosystem Integration Software Category
10.6.2021 01:00:00 EEST | Business Wire | Press release
Cleo Communications (“Cleo” or the “Company”), a global provider of ecosystem integration software solutions, has received a significant investment from an affiliate of H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with $44 billion of equity capital under management. Terms were not disclosed.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210609005913/en/
Headquartered in Rockford, Illinois, Cleo is an ecosystem integration SaaS platform company that modernizes the movement and integration of B2B enterprise data. The Cleo Integration Cloud platform provides more than 4,000 customers worldwide with strategic supply chain visibility into revenue-critical end-to-end business processes across the ecosystems of partners and customers, marketplaces, and customers’ internal applications. Cleo’s solutions drive business agility, accelerate partner onboarding, automate key business processes, and capture new revenue streams through application, B2B, and data integration technologies.
“We are extremely excited to welcome H.I.G. Capital as an investment partner in Cleo as we continue executing on our mission to redefine B2B integration in the cloud, solidifying Cleo’s position as the pioneer and global leader of the ecosystem integration software category,” said Mahesh Rajasekharan, President and CEO of Cleo. “Given their deep domain knowledge and our shared vision for creating customer value, H.I.G.’s investment clearly validates the momentum and acceleration of ecosystem integration adoption. It also underscores our mutual conviction that Cleo’s strategy of helping businesses manage rapid growth by improving supply chain visibility and control through cloud integration technology, will continue creating expansive value for our customers and their ecosystem trading partners, while rapidly accelerating Cleo’s market leadership.”
According to Gartner, the Integration Platform as a Service (iPaaS), Managed File Transfer Suites (MFT), and B2B Gateway Software (Stand-alone) subsegments in the Application Infrastructure and Middleware market, worldwide represent $5.5 billion in annual revenues in 2021 and are expected to grow to $7.1 billion by 2024.1 Cleo is disrupting these markets with its ecosystem integration platform as adoption proliferates in light of eCommerce-driven digital transformation.
“To compete successfully, companies across industries need to master increasingly complex B2B information flows and integrate the applications running the enterprise. Cleo has the platform that helps its clients meet these challenges. The Company is positioned for further growth as eCommerce and the exponential market growth of digital information flows continue to expand the need for user-friendly, rapidly deployed and feature-rich platforms like Cleo’s,” said Timur Akazhanov, Managing Director of H.I.G. “We believe Cleo offers best-in-class cloud integration platform technology following years of heavy investment in product development, which is now earning high praise from customers, and is being adopted at a robust rate. We are thrilled to partner with Mahesh and the Cleo team to continue to accelerate the Company’s growth trajectory.”
Previously, Cleo was backed by an investor group led by Alpine Investors and Peterson Partners.
UBS Investment Bank served as exclusive financial advisor to Cleo. Guggenheim Securities LLC and Harris Williams served as financial advisors to H.I.G.
About Cleo Communications
Cleo is an ecosystem integration software company whose solutions simplify the movement and integration of critical B2B enterprise data, thereby enabling business agility and business flow visibility. The Cleo Integration Cloud (“CIC”) is a cloud-based platform that brings end-to-end integration visibility across API, EDI, and non-EDI integrations and gives technical and business users the confidence and capability to rapidly onboard trading partners, enable integration between applications, and accelerate revenue-generating business processes. Headquartered in Rockford, Illinois, Cleo serves more than 4,000 customers globally with a focus on the manufacturing, wholesale & distribution, and logistics end-markets.
About H.I.G. Capital
H.I.G. is a leading global private equity and alternative assets investment firm with $44 billion of equity capital under management.* Based in Miami, and with offices in New York, Boston, Chicago, Dallas, Los Angeles, San Francisco, and Atlanta in the U.S., as well as international affiliate offices in London, Hamburg, Madrid, Milan, Paris, Bogotá, Rio de Janeiro and São Paulo, H.I.G. specializes in providing both debt and equity capital to small and mid-sized companies, utilizing a flexible and operationally focused/ value-added approach:
- H.I.G.’s equity funds invest in management buyouts, recapitalizations and corporate carve-outs of both profitable as well as underperforming manufacturing and service businesses.
- H.I.G.’s debt funds invest in senior, unitranche and junior debt financing to companies across the size spectrum, both on a primary (direct origination) basis, as well as in the secondary markets. H.I.G. is also a leading CLO manager, through its WhiteHorse family of vehicles, and manages a publicly traded BDC, WhiteHorse Finance.
- H.I.G.’s real estate funds invest in value-added properties, which can benefit from improved asset management practices.
Since its founding in 1993, H.I.G. has invested in and managed more than 300 companies worldwide. The firm's current portfolio includes more than 100 companies with combined sales in excess of $30 billion. For more information, please refer to the H.I.G. website at www.higcapital.com.
* Based on total capital commitments managed by H.I.G. Capital and affiliates.
1 Gartner, ‘Forecast: Enterprise Infrastructure Software, Worldwide, 2019-2025 1Q21 Update’, Vanitha Dsilva, Laurie Wurster, et al, 23 March 2021
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210609005913/en/
Contact information
Laura Asendio
10Fold Communications on behalf of Cleo
cleo@10fold.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
